Ionis Pharmaceuticals, Inc. (IONS) Business Profile

What it does

Ionis Pharmaceuticals is a biotechnology company that discovers, develops and commercializes RNA-targeted medicines for serious diseases. These medicines act on RNA, which carries instructions used by cells to make proteins. By changing those instructions or reducing particular proteins, Ionis aims to treat the underlying biology of a disease.

Ionis has seven marketed medicines. It sells TRYNGOLZA and DAWNZERA independently in the United States. TRYNGOLZA reduces triglycerides, a type of fat in the blood, in adults with familial chylomicronemia syndrome, a rare genetic condition. It is also approved in the United States to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia. DAWNZERA helps prevent attacks of hereditary angioedema, a condition that causes recurring episodes of severe swelling.

Other medicines reach patients through partnerships. Ionis and AstraZeneca commercialize WAINUA together in the United States for a hereditary disease that damages peripheral nerves. Biogen commercializes SPINRAZA for spinal muscular atrophy and QALSODY for a genetic form of amyotrophic lateral sclerosis. Ionis also sells TEGSEDI and WAYLIVRA through distribution and licensing partners outside the United States.

Beyond marketed medicines, Ionis develops treatments in neurology, cardiometabolic diseases and other areas of patient need. Some are wholly owned; others are developed with pharmaceutical partners. Brett Monia is chief executive officer.

How it makes money

Total revenue was $943.7 million in 2025 and $268 million in the second quarter of 2026.

Ionis earns commercial revenue from sales of medicines it sells itself and from royalties on medicines commercialized by partners. Its product sales include TRYNGOLZA and DAWNZERA in the United States and TEGSEDI and WAYLIVRA in other markets. It also earns royalties from SPINRAZA, WAINUA and QALSODY. Commercial revenue depends on continued sales of those medicines; the company has sold a minority interest in future SPINRAZA and pelacarsen royalties to Royalty Pharma.

Collaborations generate another stream of revenue. Agreements can include upfront license payments, payments for research and development services, and milestone payments tied to events in a medicine’s development or commercialization. Ionis recognizes some payments when it delivers a license and others over the period in which it performs services. These payments depend on the terms and progress of individual programs rather than a fixed subscription.

In 2025, commercial revenue increased 49 percent compared to 2024, primarily because of TRYNGOLZA product sales and higher royalty revenue. Revenue from research collaborations included a $280 million upfront payment for the global license of sapablursen to Ono. In the second quarter of 2026, commercial revenue was $119 million and research and development revenue was $149 million.

TRYNGOLZA generated $5 million in product sales in the second quarter of 2026. Ionis attributes the decline in that quarter to a reduction in its wholesale acquisition cost ahead of the expansion into severe hypertriglyceridemia. DAWNZERA generated $26 million in the same quarter.

Customers and how it sells

Ionis medicines serve patients with serious genetic, neurological and other diseases. Their use involves healthcare providers who prescribe treatment and government or third-party payers whose reimbursement policies affect access. Ionis also works with pharmaceutical companies that license, develop or commercialize its medicines.

The company sells TRYNGOLZA and DAWNZERA independently in the United States. Ionis and AstraZeneca co-commercialize WAINUA there, while AstraZeneca has exclusive rights to commercialize it outside the United States. Biogen commercializes SPINRAZA and QALSODY worldwide.

For TRYNGOLZA, Sobi is responsible for commercialization outside the United States, Canada and China. Theratechnologies is responsible for Canada. Otsuka commercializes DAWNZERA in Europe and Asia. Ionis sells TEGSEDI and WAYLIVRA in Europe through a Sobi distribution agreement, while PTC commercializes them in Brazil under license.

Ionis has said that early coverage for TRYNGOLZA in severe hypertriglyceridemia would largely run through medical exceptions while payers establish coverage criteria. Healthcare providers may need to complete prior authorizations and provide information about a patient’s prior therapy and triglyceride levels. The company also says that providers beyond those who treated familial chylomicronemia syndrome have begun prescribing TRYNGOLZA for the expanded indication.

Suppliers and costs

Ionis uses its own manufacturing facility and contract manufacturing organizations to support its medicines. Contract manufacturers make drug product and active pharmaceutical ingredients for development programs. Its manufacturing and development chemistry costs include personnel, specialized chemicals, validation batches, laboratory supplies and outside services.

Cost of sales includes manufacturing, transportation and freight, indirect manufacturing and distribution overhead, and associated period costs for TRYNGOLZA, DAWNZERA, TEGSEDI and WAYLIVRA. For recently launched products, those costs do not yet include the full cost of manufacturing: some inventory made before launch was previously recorded as research and development expense.

Research, development and patent expenses include discovery, clinical development, medical affairs, manufacturing chemistry and support costs. Selling, general and administrative expenses include commercialization staff and outside services, corporate support and certain licensing and cost-sharing payments. Ionis expects selling, general and administrative expenses to rise as it invests in independent launches.

Under the WAINUA collaboration, AstraZeneca shares development costs and pays the vast majority of U.S. medical affairs and commercial costs, as well as the costs of bringing WAINUA to market outside the United States. Ionis’s facility and contract manufacturers are subject to regulatory inspections and manufacturing requirements.

Competitive position

Ionis competes with other medicines and investigational treatments across its disease areas. SPINRAZA faces a gene therapy and an oral product for spinal muscular atrophy. DAWNZERA faces several commercial competitors in hereditary angioedema, including an oral product. WAINUA faces numerous competitors in hereditary transthyretin amyloidosis with polyneuropathy, including an oral product.

Ionis says WAINUA faces a challenge with patients who have both nerve and heart manifestations because AMVUTTRA is indicated for both polyneuropathy and cardiomyopathy. TRYNGOLZA also faces competition in familial chylomicronemia syndrome. In Angelman syndrome, Ionis is developing obudanersen and is watching data from an Ultragenyx program, although the companies’ molecules are different.

Ionis protects its medicines with product-specific patents covering their sequences, chemical modifications and methods of use. Its commercial products also have trademarks. Our reading: those protections and Ionis’s RNA-targeting expertise offer a meaningful source of differentiation, but do not prevent competing products from using other approaches to treat the same diseases.

Some products also have features relevant to patients and prescribers: WAINUA can be self-administered with an auto-injector, and DAWNZERA is an RNA-targeted preventive therapy. Our reading: convenience and product features can support adoption, but their strength as a barrier is limited by competing therapies and reimbursement decisions.

Growth opportunities

Ionis is expanding from partnered medicines into products it sells independently. The U.S. approval of TRYNGOLZA for severe hypertriglyceridemia extends the medicine beyond familial chylomicronemia syndrome. Ionis estimates that more than three million people in the United States live with severe hypertriglyceridemia. The company expects TRYNGOLZA revenue to return to growth in the second half of 2026 as the launch progresses.

DAWNZERA is another independent launch. Ionis reports adoption among patients switching from preventive treatments, those previously using only treatment for attacks and those who had not previously been treated. Ionis expects DAWNZERA to continue contributing to growth as it becomes established.

The wholly owned pipeline includes zilganersen for Alexander disease and obudanersen for Angelman syndrome. Ionis has submitted zilganersen for U.S. approval and has an expanded access program. Enrollment in the Phase III obudanersen study was completed in June 2026, and Ionis expects data in 2027. ION337 has entered clinical development for Dravet syndrome.

Partnered programs provide additional development opportunities. GSK is responsible for bepirovirsen for chronic hepatitis B; Ionis says it has a U.S. target action date. Ono has licensed sapablursen, and AstraZeneca and Ionis have developed eplontersen together. However, eplontersen did not meet the primary efficacy endpoint in its heart-disease study. It was reported on 27 October 2026 that the pelacarsen study did not show a statistically significant reduction in major cardiovascular events compared with placebo.

Structural risks

• Commercial execution and reimbursement. Ionis has limited experience commercializing medicines and must continue investing in its capabilities. Market acceptance depends on factors including payer coverage, demonstrated safety and efficacy, cost, convenience and the scope of marketing authorizations.

• Clinical and regulatory outcomes. Studies may be delayed or produce negative or inconclusive results, and regulators can delay, limit or deny approval. Eplontersen did not meet the primary endpoint in its heart-disease study, and it was reported on 27 October 2026 that pelacarsen did not show a statistically significant reduction in major cardiovascular events compared with placebo.

• Competition. Existing and future products may be safer, more effective, less costly or more convenient, or obtain more favorable reimbursement. Ionis medicines already face competing treatments in several markets.

• Partner dependence. Partners develop, fund and commercialize many Ionis medicines. Ionis relies on them for activities including development of pelacarsen and bepirovirsen and commercialization of SPINRAZA and QALSODY.

• Costs and financing. Launches and development require continued spending. Ionis generated a $381.4 million net loss in 2025 and has used debt, equity and sales of future royalties to finance operations. Its cost of sales for newer launches does not yet reflect the full manufacturing cost of inventory made after launch.

Bottom line

Our reading

Ionis combines a royalty and collaboration business with a growing operation that sells medicines directly. Its prospects depend on converting the TRYNGOLZA expansion and other launches into sustained product sales while funding research and commercialization. Partnerships help finance and distribute medicines, but leave Ionis dependent on partners and clinical results; the eplontersen and reported pelacarsen setbacks illustrate that pipeline outcomes can constrain those opportunities.